Close Menu

NEW YORK — Biodesix said today that it has signed an agreement to acquire Oncimmune's US operations and the US rights to the firm's blood-based incidental pulmonary nodule test EarlyCDT Lung.

The test, which UK-based Oncimmune launched in the US in 2012, measures levels of seven auto-antibodies to tumor-associated antigens. It is designed to detect all forms of lung cancer at any stage.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.